Rebuttal to 8/25/21 Cassava Sciences Press Release
WASHINGTON--(BUSINESS WIRE)--Aug 26, 2021--
On August 18, 2021, Jordan Thomas of Labaton Sucharow filed a Citizen Petition to the FDA on behalf of our clients who collectively have expertise in neuroscience, drug discovery, biochemistry, and finance. They also hold short positions in Cassava stock.
The Company responded on August 25, 2021 to the Citizen Petition with a press release in which they provided a rebuttal to the specific complaints in the Citizen Petition and denied any wrongdoing. Since the issuance of the press release, leading international experts on scientific integrity have independently validated key aspects of the Citizen Petition and have posted comments on PubPeer. On Twitter, they have critically questioned the Company’s response.
Notably, commenting generally on the Western blots in question— those that reportedly form the foundational data for simufilam (PTI-125) as a treatment for Alzheimer’s Disease —to Retraction Watch, David Vaux, deputy director of science integrity and ethics at the Australian Walter and Eliza Hall Institute of Medical Research (WEHI) stated: “It is not conceivable that features in the images (such as apparent duplications) arose due to coincidence (chance) or accident, leaving the only plausible explanation being that the images were deliberately falsified or fabricated.”
View source version on businesswire.com:https://www.businesswire.com/news/home/20210826005765/en/
CONTACT: Media Contact:
Profile for Labaton Sucharow
KEYWORD: UNITED STATES NORTH AMERICA DISTRICT OF COLUMBIA
INDUSTRY KEYWORD: HEALTH LEGAL OTHER SCIENCE CLINICAL TRIALS SCIENCE BIOTECHNOLOGY
SOURCE: Labaton Sucharow
Copyright Business Wire 2021.
PUB: 08/26/2021 04:50 PM/DISC: 08/26/2021 04:51 PM